AA
CRNX icon

AlphaCentric Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

AlphaCentric Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-82,000
Closed -$2.44M – 241
2023
Q3 		$2.44M Buy
82,000
+35,000
+74% +$721K 1.38% 19
2023
Q2 		$847K Buy
+47,000
New +$937K 0.47% 73

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AlphaCentric Advisors's CRNX Position: Q4 2023 in Review

AlphaCentric Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 82,000 shares — an estimated $2.44M sold.

AlphaCentric Advisors first reported a position in CRNX in Q2 2023 and held it in 2 quarters. The position peaked at $2.44M in Q3 2023. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

  • AlphaCentric Advisors reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • AlphaCentric Advisors sold 82,000 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $2.44M.
  • AlphaCentric Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • AlphaCentric Advisors's Crinetics Pharmaceuticals position peaked at $2.44M in Q3 2023.
  • 181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.